1. CNS Cluster Addiction Drug Development Pipeline Review, 2017 Published: May 2017 Single User PDF: US$ 3995 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any.sales@reportsandreports.com 1 © ReportsnReports.com / Contact sales@reportsandreports.com

2. CNS Cluster Addiction Drug Development Pipeline Review, 2017 The Market Research Report on CNS Cluster Pipeline Drug Addiction development states the symptoms for Alcohol Addiction, Drug Addiction, Nicotine Addiction and Opium (Opioid) Addiction. The CNS Cluster Pipeline Drug Addiction report provides comprehensive information on the therapeutics under development, and key players involved in therapeutic development for features dormant and discontinued projects. Drug addiction, also called substance dependence or chemical dependency, is a disease that is characterized by a destructive pattern of drug abuse that leads to significant problems involving tolerance to or withdrawal from the substance. There are a total of 67 products in development for this indication, by 38 companies and 16 academic institutions. Access Complete Report at: http://www.reportsnreports.com/reports/1001381-cns-cluster- addiction-drug-development-pipeline-review-2017.html.http://www.reportsnreports.com/reports/1001381-cns-cluster- addiction-drug-development-pipeline-review-2017.html Offers from 10th May 2017 to 2nd June 2017 All reports priced >=1,000 – 20% Discount – Single User ; 25% Discount – Global Site License. Buy 2 Reports Get 1 Report Free Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 2 © ReportsnReports.com / Contact sales@reportsandreports.com

3. CNS Cluster Addiction Drug Development Pipeline Review, 2017 Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression and restlessness, inability to control drinking and violent behavior. There are a total of 38 products in development for this indication, by 29 companies and five academic institutions. Nicotine addiction also called tobacco dependence is an addiction to tobacco products caused by the drug nicotine. There are a total of 19 products in development for this indication, by 13 companies and 5 academic institutions. The majority of companies are developing single pipeline program in this space, while Omeros are developing two. Finally, opioid addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). There are a total of 33 products in development for this indication, by 23 companies and three academic institutions. Inquire for Discount http://www.reportsnreports.com/contacts/discount.aspx?name=1001381.http://www.reportsnreports.com/contacts/discount.aspx?name=1001381 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 3© ReportsnReports.com / Contact sales@reportsandreports.com

4. CNS Cluster Addiction Drug Development Pipeline Review, 2017 There is a substantial degree of overlap between these indications in terms of the types of molecular target which are being studied. The mu and kappa-opioid receptors are the dominant molecular target across alcohol, drug and opioid addiction, and other neurotransmitter receptors such as the cannabinoid and dopamine receptors are common molecular targets across the three. In contrast, while such neurotransmitter receptors are present in the nicotine addiction pipeline, the opioid receptors are not, and the dominant molecular target is the orexin receptor type 1. Key Companies Operating in this Pipeline include: Astraea Therapeutics, Addex therapeutics, The University of Kansas, Embera NeuroTherapeutics, InterveXion Therapeutics, Omeros, Opiant Pharmaceuticals and Orexigen Therapeutics, Abbvie, Astraea Therapeutics, Lochola Research and SK Biopharmaceuticals, Indivior, INSYS Therapeutics, Omeros, Pfizer and Zynerba Pharmaceuticals. Buy a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=1001381.http://www.reportsnreports.com/purchase.aspx?name=1001381 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 4© ReportsnReports.com / Contact sales@reportsandreports.com

5. CNS Cluster Addiction Drug Development Pipeline Review, 2017 Scope of the Report Which companies are the most active within the pipeline for addiction therapeutics? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in the field of addiction therapeutics? Buy a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=1001381.http://www.reportsnreports.com/purchase.aspx?name=1001381 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. sales@reportsandreports.com 5 © ReportsnReports.com / Contact sales@reportsandreports.com5

6. About ReportsnReports ReportsnReports.comReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Contact: Ritesh Tiwari Maharashtra, India. Tel: +1-888-391-5441 sales@reportsnreports.com 6© ReportsnReports.com / Contact sales@reportsandreports.com